AVEO Pharmaceuticals, Inc (NASDAQ:AVEO) is a company that manufactures biopharmaceutical products that help treat acute medical conditions. Currently, it seeks to further develop tivozanib which is its most recent candidate. The company in conjunction with EUSA Pharma unveiled results from TiNivo study.
Current state of affairs
These companies admit that this Phase 2 study pulled along with several challenges. However, they are glad it inspires hope that they will succeed at handling metastatic renal cell carcinoma. AVEO terms oral (PO) tivozanib a critical element in the study. It seeks to see the way it acts when combined with intravenous (IV) nivolumab.
The business guru unveiled the results at the European Society of Medical Oncology congress. The responsible management conducts this congress on a yearly basis. Researchers conducted the study among about 28 patients. According to them, the number was ideal for the Phase 1b/2 study.
Researchers sought to find out important aspects such as anti-tumor activity, tolerability and above all the safety of the dose. They admit that the combination was ideal. The associated tolerability even exceeded their set expectations. They say that hypertension was one of the extreme events associated with the treatment and that it affected about 60% of patients.
Genitourinary Oncology Committee’s ex-Chairman Doctor Bernard Escudier opined, “The ability to give a VEGF inhibitor and immuno-oncology agent both at full dose and strength could serve to deliver both improved outcomes and an improved patient experience.”
A closer outlook
The official expects that soon he will be in a position to better understand the full potential of tivozanib. Escudier counts on the randomized study that is currently underway since he believes it will reveal more regarding the immunotherapy.
The President of AVEO Michael Bailey has spoken in relation to the various cancers. According to the leader, the IO-TKI combinations have proven effective which a stride towards the right direction.
Bailey asserts that as a company they will keep focusing on expanding their clinical strategies. The leader believes in tivozanib and its remarkable effects on metastatic RCC and promises they will soon be doing much more.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.